

IN THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A composition comprising a TNP-470 conjugated to a polymer, wherein the polymer is water soluble and has a molecular weight not greater than 60 kDa, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
2. (Canceled)
3. (Original) The composition of claim 1, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
4. (Canceled)
5. (Original) The composition of claim 1, further comprising a peptide linker between the TNP-470 and the polymer.
6. (Original) The composition of claim 1, further comprising a targeting ligand.

- $$x \left[\begin{array}{c} \text{CH}_3 \\ | \\ -\text{C}- \\ | \\ \text{H} \end{array} \right]_2 \left[\begin{array}{c} \text{CO} \\ | \\ \text{NH} \\ | \\ \text{CH}_2 \\ | \\ \text{CHOH} \\ | \\ \text{CH}_3 \end{array} \right] y$$
-
- $$\left[\begin{array}{c} \text{CO} \\ | \\ \text{NH} \\ | \\ \text{CH}_2 \\ | \\ \text{CO} \\ | \\ \text{NH} \\ | \\ \text{HC}-\text{C}-\text{C}_6\text{H}_5 \\ | \quad | \quad | \\ \text{H} \quad \text{H}_2 \end{array} \right] z$$
-
- $$\left[\begin{array}{c} \text{CO} \\ | \\ \text{NH} \\ | \\ \text{HC}-\text{C}-\text{C}(\text{CH}_3)_2 \\ | \quad | \quad | \\ \text{H} \quad \text{H}_2 \end{array} \right] w$$
-
- $$\left[\begin{array}{c} \text{CO} \\ | \\ \text{NH} \\ | \\ \text{CH}_2 \\ | \\ \text{CO} \\ | \\ \text{NH} \\ | \\ (\text{CH}_2)_2 \end{array} \right] v$$
-
- $$\left[\begin{array}{c} \text{O} \\ || \\ \text{N} \\ / \quad \backslash \\ \text{O} \quad \text{O} \\ | \quad | \\ \text{H} \quad \text{OMe} \\ | \quad | \\ \text{O} \quad \text{O} \\ | \quad | \\ \text{CH}_2 \quad \text{CH}_2 \\ | \quad | \\ \text{CH}_3 \quad \text{CH}_3 \end{array} \right]$$

8. (Previously presented) A method of treating an angiogenic disease comprising administering a composition of claim 1 to a mammal in need thereof, wherein the


angiogenic disease is a solid tumor, a lymphoma, a leukemia, diabetic retinopathy or macular degeneration.

9. (Canceled)
10. (Previously presented) A method for decreasing neurotoxicity of TNP-470, comprising conjugating the TNP-470 to a polymer, wherein the polymer is water soluble and has a molecular weight not greater than 60 kDa.
11. (Canceled)
12. (Previously presented) The method of claim 10, wherein the polymer has a molecular weight in the range of 15 to 40 kDa.
13. (Original) The method of claim 10, wherein the polymer is a hydroxypropyl(meth)acrylamide-methacrylic acid copolymer.
14. (Original) The method of claim 10, further comprising a peptide linker between the antiangiogenic agent and the polymer.

[illegible]

16. (Original) The method of claim 15, wherein y is 5-10 and x is 90-95.

107332893.1



~~Wherein~~ wherein x is 90-95 and y is 5-10.